MedOptions is growing. The nation’s leading provider of behavioral health services to skilled nursing and assisted living facilities continues to expand and has local opportunities for nurse practitioners to join our team of 800 clinicians and support staff. MedOptions partners with skilled nursing and assisted living facilities across the nation to provide expert behavioral health services, improving the overall mental health in elderly patients through the use of memory care evaluations, medication management, and behavioral interventions. Our multidisciplinary team consists of psychiatrists, nurse practitioners, clinical psychologists and clinical social workers. They are experienced in dementia care and Alzheimer’s care, long term behavioral health care in elderly populations, and memory care services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

GRAF ACQUISITION CORP. IV AND NKGEN BIOTECH, INC. ANNOUNCE EFFECTIVENESS OF FORM S-4 FOR PROPOSED BUSINESS COMBINATION

Globenewswire | August 16, 2023

news image

Graf Acquisition Corp. IV and NKGen Biotech, Inc. on August 14, 2023 announced that Graf’s registration statement on Form S-4 relating to the previously announced business combination (the “Business Combination”) with NKGen, has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). Graf also commenced mailing the definitive proxy statement/prospectus on August 14, 2023, which was included in the Registration Statement, relating to...

Read More

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

news image

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

news image

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More

LABCORP'S CRO UNIT COVANCE DOUBLES DOWN ON CELL, GENE THERAPY OFFERINGS

FierceBiotech | January 21, 2020

news image

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

Read More
news image

Medical, Industry Outlook

GRAF ACQUISITION CORP. IV AND NKGEN BIOTECH, INC. ANNOUNCE EFFECTIVENESS OF FORM S-4 FOR PROPOSED BUSINESS COMBINATION

Globenewswire | August 16, 2023

Graf Acquisition Corp. IV and NKGen Biotech, Inc. on August 14, 2023 announced that Graf’s registration statement on Form S-4 relating to the previously announced business combination (the “Business Combination”) with NKGen, has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). Graf also commenced mailing the definitive proxy statement/prospectus on August 14, 2023, which was included in the Registration Statement, relating to...

Read More
news image

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More
news image

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More
news image

LABCORP'S CRO UNIT COVANCE DOUBLES DOWN ON CELL, GENE THERAPY OFFERINGS

FierceBiotech | January 21, 2020

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

Read More